Search

Your search keyword '"Fine, Nowell"' showing total 665 results
Start Over Author "Fine, Nowell"
665 results on '"Fine, Nowell"'

4. Comprehensive Geriatric Assessment to Optimize the Management of Older Patients With Transthyretin Cardiac Amyloidosis

Author

Fumagalli, Carlo, Maurer, Mathew S., Fontana, Marianna, Fine, Nowell, Gillmore, Julian, Goyal, Parag, Nakagawa, Shunichi, Musumeci, Beatrice, Grogan, Martha, Marfella, Raffaele, Limongelli, Giuseppe, Bo, Mario, Longhi, Simone, Cuddy, Sarah, Masri, Ahmad, Olivotto, Iacopo, Perfetto, Federico, Ungar, Andrea, Marchionni, Niccolò, and Cappelli, Francesco

Published
2024
Full Text
View/download PDF

5. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS

Author

Emdin, Michele, Hanna, Mazen, Azevedo, Olga, Lino Cirami, Calogero, Gonzalez Costello, Jose, Slosky, David, Moelgaard, Henning, Nativi Nicolau, Jose, Hummel, Scott, Jeon, Eun-Seok, Fine, Nowell, Murali, Srinivas, Miller, Edward, Shah, Sanjiv, Witteles, Ronald, Waddington-Cruz, Marcia, Lenihan, Daniel, Sekijima, Yoshiki, Van Cleemput, Johan, Correia, Edileide de Barros, Cariou, Eve, Quan, Dianna, Freimer, Miriam, Steidley, David, Hüsing-Kabar, Anna, Plante-Bordeneuve, Violaine, Nienhuis, Hans, Wixner, Jonas, Ralph, Jeffrey, Ventura, Hector, Zivkovic, Sasa, Delgado, Diego, Fernandéz Torrón, Roberto, Gottlieb, Stephen, Cotts, William, Tallaj, Jose, Brunkhorst, Robert, Polydefkis, Michael, Mueller, Christopher, Tschoepe, Carsten, Gonzalez Moreno, Juan, Sarswat, Nitasha, Luo, Jin, Tauras, James, Warner, Alberta, Mora-Ayestaran, Nerea, Dispenzieri, Angela, Kristen, Arnt V., Maurer, Mathew S., Diemberger, Igor, Drachman, Brian M., Grogan, Martha, Gupta, Pritam, Glass, Oliver, Amass, Leslie, and Garcia-Pavia, Pablo

Published
2024
Full Text
View/download PDF

7. The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology

Author

STERN, LILY K., GRODIN, JUSTIN L., MAURER, MATHEW S., RUBERG, FREDERICK L., PATEL, AYAN R., KHOURI, MICHEL G., ROTH, LORI R., ARAS, MANDAR A., BHARDWAJ, ANJU, BHATTACHARYA, PRIYANKA, BRAILOVSKY, YEVGENIY, DRACHMAN, BRIAN M., EBONG, IMO A., FINE, NOWELL M., GAGGIN, HANNA, GOPAL, DEEPA, GRIFFIN, JAN, JUDGE, DANIEL, KIM, PAUL, MITCHELL, JOSHUA, MITTER, SUMEET S., MOHAN, RAJEEV C., RAMOS, HANNIA, REYENTOVICH, ALEX, SHEIKH, FAROOQ H., SPERRY, BRETT, CARTER, SPENCER, UREY, MARCUS, VAISHNAV, JOBAN, VEST, AMANDA R., KITTLESON, MICHELLE M., and PATEL, JIGNESH K.

Published
2024
Full Text
View/download PDF

21. Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy

Author

Purmah, Yanish, Cornhill, Aidan, Lei, Lucy Y., Dykstra, Steven, Mikami, Yoko, Satriano, Alessandro, Labib, Dina, Flewitt, Jacqueline, Rivest, Sandra, Sandonato, Rosa, Seib, Michelle, Howarth, Andrew G., Lydell, Carmen P., Heydari, Bobak, Merchant, Naeem, Bristow, Michael, Kolman, Louis, Fine, Nowell M., and White, James A.

Published
2022
Full Text
View/download PDF

25. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

Author

Barroso, Fabio Adrian, Van Cleemput, Johan, Fine, Nowell, Schmidt, Hartmut, Gess, Burkhard, Moelgaard, Henning, Planté-Bordeneuve, Violaine, Adams, David, Inamo, Jocelyn, Vita, Giuseppe, Cirami, Calogero Lino, Luigetti, Marco, Emdin, Michele, Sekijima, Yoshiki, Yamashita, Taro, Jeon, Eun-Seok, Gonzalez Duarte Briseno, Maria Alejandra, Nienhuis, Hans, Azevedo, Olga, Campistol Plana, Josep Maria, Moreno, Juan Gonzalez, Costello, Jose Gonzalez, Wixner, Jonas, Parman, Yesim, Shah, Sanjiv, Quan, Dianna, Marburger, Tessa, Polydefkis, Michael, Gottlieb, Stephen, Ralph, Jeffrey, Sarswat, Nitasha, Luo, Jin, Murali, Srinivas, Cotts, William, Drachman, Brian, Steidley, David, Hummel, Scott, Slosky, David, Ventura, Hector, Jacoby, Daniel, Hoffman, James, Tauras, James, Zivkovic, Sasa, Tallaj, Jose, Lenihan, Daniel, Mueller, Christopher, Nativi-Nicolau, Jose, Siu, Alfonso, Dispenzieri, Angela, Maurer, Mathew S., Rapezzi, Claudio, Kristen, Arnt V., Garcia-Pavia, Pablo, LoRusso, Samantha, Waddington-Cruz, Márcia, Lairez, Olivier, Witteles, Ronald, Chapman, Doug, Amass, Leslie, and Grogan, Martha

Published
2021
Full Text
View/download PDF

29. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy

Author

Shah, Sanjiv J., Fine, Nowell, Garcia-Pavia, Pablo, Klein, Allan, Fernandes, Fabio, Weissman, Neil, Maurer, Mathew, Boman, Kurt, Gundapaneni, Balarama, Sultan, Marla, Elliott, Perry, Shah, Sanjiv J., Fine, Nowell, Garcia-Pavia, Pablo, Klein, Allan, Fernandes, Fabio, Weissman, Neil, Maurer, Mathew, Boman, Kurt, Gundapaneni, Balarama, Sultan, Marla, and Elliott, Perry

Abstract

IMPORTANCE: Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized. OBJECTIVE: To examine the effect of tafamidis on cardiac function in patients with ATTR-CM. DESIGN, SETTING, AND PARTICIPANTS: This was an exploratory, post hoc analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), a multicenter, international, double-blind, placebo-controlled phase 3 randomized clinical trial conducted from December 2013 to February 2018. The ATTR-ACT included 48 sites in 13 counties and enrolled patients aged 18 to 90 years with ATTR-CM. Data were analyzed from July 2018 to September 2023. INTERVENTION: Patients were randomized to tafamidis meglumine, 80 mg or 20 mg, or placebo for 30 months. MAIN OUTCOMES AND MEASURES: Patients were categorized based on left ventricular (LV) ejection fraction at enrollment as having heart failure with preserved ejection fraction (≥50%), mildly reduced ejection fraction (41% to 49%), or reduced ejection fraction (≤40%). Changes from baseline to month 30 in LV ejection fraction, LV stroke volume, LV global longitudinal strain, and the ratio of early mitral inflow velocity to septal and lateral early diastolic mitral annular velocity (E/e′) were compared in patients receiving tafamidis, 80 mg, vs placebo. RESULTS: A total of 441 patients were randomized in ATTR-ACT, and 436 patients had available echocardiographic data. Of 436 included patients, 393 (90.1%) were male, and the mean (SD) age was 74 (7) years. A total of 220 (50.5%), 119 (27.3%), and 97 (22.2%) had heart failure with preserved, mildly reduced, and reduced LV ejection fraction, respectively. Over 30 months, there was less pronounced worsening in 4 of the echocardiographic measures in patients receiving tafamidis, 80 mg (n = 176), vs placebo (n = 177) (least squares mean difference: LV stroke volume, 7.02 mL

Published
2024
Full Text
View/download PDF

31. Abstract 10325: Feasibility and Predictive Utility of Three-Dimensional Myocardial Deformation Analysis From Multi-Phase Computed Tomography Angiography in Transcatheter Aortic Valve Replacement

Author

Rabbani, Mohamad, Satriano, Alessandro, Lydell, Carmen, Bristow, Mike, Fatehi Hassanabad, Ali, Mustafa Alhussein, Muhammad M, Liang, Zhiying, Tao, Eric, Bizios, Anna, Adams, Corey, Fine, Nowell, Howarth, Andrew G, Kent, William, Chu, Michael W, and White, James

Published
2022
Full Text
View/download PDF

32. Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience.

Author

Shahi, Karan, Miller, Robert J. H., Dykstra, Steven, Feng, Yuanchao, Howlett, Jonathan G., Jimenez-Zepeda, Victor, Veenhuyzen, Jan, White, James A., and Fine, Nowell M.

Subjects
SYSTOLIC blood pressure, KIDNEY physiology, TRANSTHYRETIN, MORTALITY, COMPETING risks, CARDIAC amyloidosis
Abstract

Background: Tafamidis is a costly therapy that improves outcomes for patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), although significant knowledge gaps exist for predicting longer-term response to treatment. The purpose of this study was to examine baseline predictors of adverse outcomes and their association with tafamidis treatment in comparison with those untreated in a clinical cohort from a Canadian ATTR-CM referral center. Methods: Patients with a confirmed diagnosis of ATTR-CM were included. Multivariable modeling was used to identify baseline variables associated with the primary outcome of all-cause mortality and secondary outcomes of cardiovascular mortality or hospitalization. Cox proportional hazard and competing risk analyses were used, with tafamidis modeled as a time-varying covariate. Results: In total, 139 ATTR-CM patients were included, with a median age of 80.9 years [74.3–86.6 years], from 2011 to 2022. The mean follow-up was 2.9 ± 1.8 years. Eighty (55%) patients were treated with tafamidis. All-cause mortality and cardiovascular mortality alone were associated with the following baseline variables: age, clinical frailty scale, systolic blood pressure, renal function, and right ventricular size and function (all p < 0.05), with no identified interactions with tafamidis treatment. Only baseline renal function was associated with cardiovascular hospitalization (p < 0.05). Conclusion: Important baseline variables associated with adverse ATTR-CM disease outcomes included renal function, systolic blood pressure, frailty, and right ventricular size and function. The risk factors were independent of treatment with tafamidis. These findings may help improve risk stratification for determining eligibility for ATTR-CM therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.

Author

Lewis, Ellen, Fine, Nowell, McCulloch, Sylvia, Tay, Jason, Duggan, Peter, Neri, Paola, Bahlis, Nizar, and Jimenez-Zepeda, Victor H.

Subjects
*PROGRESSION-free survival, *AMYLOIDOSIS, *CARDIAC patients, *DOXYCYCLINE, *CARDIAC amyloidosis, *BORTEZOMIB
Abstract

Background: Pre-clinical and retrospective data suggest that doxycycline added to treatment regimens has benefit in AL amyloidosis. However, a recent multicenter, open-label, randomized controlled trial in AL amyloidosis patients treated with CyBorD did not demonstrate a progression-free survival (PFS) or cardiac PFS benefit with added doxycycline. Objective: The main objective of this study was to explore the role of doxycycline combined with bortezomib-containing regimens (BCRs) for newly diagnosed AL amyloidosis patients with cardiac involvement and to compare them with a cohort of concurrent patients treated with BCR only. Material and Methods: AL amyloidosis patients, newly diagnosed between January 2012 and March 2022, who were treated with BCR at the Amyloidosis Program of Calgary (APC) were evaluated. Results: Sixty-four concurrent patients were identified. Thirty-nine patients received doxycycline in addition to BCR (BCR-D) for a median of 8 months. The overall response rate was similar among the groups. No significant differences in VGPR/CR, dFLC at 1 month, time to first response, time to best response, or organ responses were noted between the BCR alone and BCR-D groups. Summary and Conclusions: Our retrospective study demonstrated that doxycycline combined with BCR failed to prolong OS, PFS, or cardiac responses compared with BCR alone in patients with cardiac AL amyloidosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis

Author

Fine, Nowell M., Davis, Margot K., Anderson, Kim, Delgado, Diego H., Giraldeau, Genevieve, Kitchlu, Abhijat, Massie, Rami, Narayan, Jane, Swiggum, Elizabeth, Venner, Christopher P., Ducharme, Anique, Galant, Natalie J., Hahn, Christopher, Howlett, Jonathan G., Mielniczuk, Lisa, Parent, Marie-Claude, Reece, Donna, Royal, Virginie, Toma, Mustafa, Virani, Sean A., and Zieroth, Shelley

Published
2020
Full Text
View/download PDF

38. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

Author

O’Meara, Eileen, McDonald, Michael, Chan, Michael, Ducharme, Anique, Ezekowitz, Justin A., Giannetti, Nadia, Grzeslo, Adam, Heckman, George A., Howlett, Jonathan G., Koshman, Sheri L., Lepage, Serge, Mielniczuk, Lisa M., Moe, Gordon W., Swiggum, Elizabeth, Toma, Mustafa, Virani, Sean A., Zieroth, Shelley, De, Sabe, Matteau, Sylvain, Parent, Marie-Claude, Asgar, Anita W., Cohen, Gideon, Fine, Nowell, Davis, Margot, Verma, Subodh, Cherney, David, Abrams, Howard, Al-Hesayen, Abdul, Cohen-Solal, Alain, D’Astous, Michel, Delgado, Diego H., Desplantie, Olivier, Estrella-Holder, Estrellita, Green, Lee, Haddad, Haissam, Harkness, Karen, Hernandez, Adrian F., Kouz, Simon, LeBlanc, Marie-Hélène, Lee, Douglas, Masoudi, Frederick A., McKelvie, Robert S., Rajda, Miroslaw, Ross, Heather J., and Sussex, Bruce

Published
2020
Full Text
View/download PDF

39. Sex-based differences in the phenotypic expression and prognosis of idiopathic non-ischaemic cardiomyopathy: a cardiovascular magnetic resonance study

Author

Mallabone, Maggie, primary, Labib, Dina, additional, Abdelhaleem, Ahmed, additional, Dykstra, Steven, additional, Thompson, Richard B, additional, Paterson, D Ian, additional, Thompson, Sam K, additional, Hasanzadeh, Fereshteh, additional, Mikami, Yoko, additional, Rivest, Sandra, additional, Flewitt, Jacqueline, additional, Feng, Yuanchao, additional, Macdonald, Matthew, additional, King, Melanie, additional, Bristow, Michael, additional, Kolman, Louis, additional, Howarth, Andrew G, additional, Lydell, Carmen P, additional, Miller, Robert J H, additional, Fine, Nowell M, additional, and White, James A, additional

Published
2024
Full Text
View/download PDF

40. Biventricular CMR Strain-based Phenotyping for the Prediction of Cardiovascular Outcomes in Cardiac Amyloidosis

Author

Labib, Dina, primary, White, Brooke V, additional, Multani, Asmi, additional, Sarak, Bradley, additional, Dykstra, Steven, additional, Hasanzadeh, Fereshteh, additional, Feng, Yuanchao, additional, MacDonald, Matthew, additional, King, Melanie, additional, Rivest, Sandra, additional, Flewitt, Jacqueline, additional, Howarth, Andrew G., additional, Lydell, Carmen P., additional, Miller, Robert JH, additional, Fine, Nowell M, additional, and White, James A, additional

Published
2024
Full Text
View/download PDF

41. Comparison of Multi-chamber CMR Phenotype and Clinical Outcomes in ATTR versus AL Cardiac Amyloidosis

Author

Labib, Dina, primary, White, Brooke V, additional, Sarak, Bradley, additional, Multani, Asmi, additional, Dykstra, Steven, additional, Hasanzadeh, Fereshteh, additional, Feng, Yuanchao, additional, MacDonald, Matthew, additional, King, Melanie, additional, Rivest, Sandra, additional, Flewitt, Jacqueline, additional, Howarth, Andrew G., additional, Lydell, Carmen P., additional, Miller, Robert JH, additional, Fine, Nowell M, additional, and White, James, additional

Published
2024
Full Text
View/download PDF

44. Exploration of Geometric Deep Learning FBom 3D Cardiac Shape Models for the Classification of Cardiac Amyloid Sub-type FBom 2D Cine Cardiovascular Magnetic Resonance Imaging

Author

Marianchuk, Rylan, primary, Dykstra, Steven, additional, Labib, Dina, additional, Ghosh, Tapotosh, additional, Flewitt, Jacqueline, additional, Sarak, Bradley, additional, Rivest, Sandra, additional, Miller, Robert, additional, Fine, Nowell, additional, Maleki, Farhad, additional, and White, James, additional

Published
2024
Full Text
View/download PDF

45. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable

Author

Brannagan, III, Thomas H., Auer-Grumbach, Michaela, Berk, John L., Briani, Chiara, Bril, Vera, Coelho, Teresa, Damy, Thibaud, Dispenzieri, Angela, Drachman, Brian M., Fine, Nowell, Gaggin, Hanna K., Gertz, Morie, Gillmore, Julian D., Gonzalez, Esther, Hanna, Mazen, Hurwitz, David R., Khella, Sami L., Maurer, Mathew S., Nativi-Nicolau, Jose, Olugemo, Kemi, Quintana, Luis F., Rosen, Andrew M., Schmidt, Hartmut H., Shehata, Jacqueline, Waddington-Cruz, Marcia, Whelan, Carol, and Ruberg, Frederick L.

Published
2021
Full Text
View/download PDF

50. Feasibility of Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial

Author

Fine, Nowell M., primary, Litwin, Owen, additional, Kent, William D.T., additional, Holloway, Daniel D., additional, Roy, Jill, additional, Miller, Robert J.H., additional, Chih, Sharon, additional, Davey, Ryan A., additional, Isaac, Debra L., additional, Sharma, Nakul, additional, Lyons, Kristin J., additional, and Howlett, Jonathan G., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results